title: Conjunctival hemorrhagic events associated with imatinib mesylate.
abstract: Imatinib mesylate (IM) is used in the targeted therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors. It is well tolerated and leads to no higher incidence of hemorrhagic events than other therapies. Of 87 patients we treated with IM for a minimum of 3 months, 10 patients (11%) developed unilateral or bilateral conjunctival hemorrhage (CH). No other hemorrhagic events were observed during follow-up, except for CH recurrence in 6 cases (7%). Because there was no other obvious reason for such a high incidence of CH, we hypothesize drug hypersensitivity or ocular irritation induced by IM treatment.
authors.affiliation: Ematologia II-Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Via Francesco Sforza 35, Milan, Italy.
authors.forename: Franca
authors.initials: F
authors.lastname: Radaelli
authors.forename: Claudia
authors.initials: C
authors.lastname: Vener
authors.forename: Francesco
authors.initials: F
authors.lastname: Ripamonti
authors.forename: Alessandra
authors.initials: A
authors.lastname: Iurlo
authors.forename: Mariangela
authors.initials: M
authors.lastname: Colombi
authors.forename: Andrea
authors.initials: A
authors.lastname: Artoni
authors.forename: Gianluigi
authors.initials: G
authors.lastname: Reda
authors.forename: Giorgio Lambertenghi
authors.initials: GL
authors.lastname: Deliliers
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D003229:Conjunctival Diseases / Q000139:chemically induced* / Q000473:pathology; D004342:Drug Hypersensitivity / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy / Q000473:pathology; D006470:Hemorrhage / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015994:Incidence; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate